The makers of the two recently approved PSCK9 cholesterol-lowering drugs played up their products' “significant” value to high-risk patients after a non-profit group this week concluded the products are significantly overpriced and unaffordable to health plans. The non-profit research group that analyzed the effectiveness and price of the new class of LDL cholesterol-lowering medications found their value-based prices to be roughly three times the existing wholesale cost, and seven times over the price needed to fall within the current budget...
You've followed a link to an article or document on InsideHealthPolicy.com.
There are two ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Sign up for a trial subscription.